SCHEMBL2247701

SCHEMBL2247701

CC(C)C[C@H](C(=O)N1CCN(c2ccc(-c3ccccc3)cc2)C[C@H]1C)[C@H](O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
FAAH O00519 2/20 0.40
CTSB P07858 3/20 0.39
CTSS P25774 3/20 0.39
CTSK P43235 3/20 0.39
SCD5 Q86SK9 1/20 0.38
CHRM4 P08173 3/20 0.38
SLC6A7 Q99884 2/20 0.38
AGTR2 P50052 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
AOC3 Q16853 1/20 0.38
SMO Q99835 2/20 0.37
CTSL P07711 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252345 0.92 FAAH (0.42) FAAHCHRM4SLC6A7CHRM2CHRM1
SCHEMBL2245046 0.90 FAAH (0.46) FAAH
SCHEMBL3872566 0.90 MMP2 (0.44) GAACTSBCTSSCTSKCHRM4
SCHEMBL2249536 0.90 MMP2 (0.44) GAACTSBCTSSCTSKCHRM4
SCHEMBL3879190 0.89 FAAH (0.37) GAAFAAHCTSBCTSSCTSK
SCHEMBL2249201 0.89 FAAH (0.37) GAAFAAHCTSBCTSSCTSK
SCHEMBL2244302 0.89 SMN1; SMN2 (0.41) FAAHCHRM4SLC6A7CHRM2CHRM1
SCHEMBL3867299 0.87 HSD11B1 (0.40) GAAFAAHCTSBCTSSCTSK
SCHEMBL2244549 0.87 HSD11B1 (0.40) GAAFAAHCTSBCTSSCTSK
SCHEMBL2250358 0.87 FAAH (0.48) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263628-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2011-10-27 US claimed
US-8008302-B2 ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis MERCK SERONO SA (CH) 2011-08-30 US claimed
EP-1771421-B1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF SERONO LAB (CH) 2009-04-29 EP claimed
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-01-24 US claimed
US-8008302-B2 ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis MERCK SERONO SA (CH) 2011-08-30 US disclosed
EP-1771421-B1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF SERONO LAB (CH) 2009-04-29 EP disclosed
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263628-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF HNMT, HCAR2, HPGD GAA 2031/4885FAAH 88/4885CTSB 558/4885
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof HCAR2, HNMT, HPGD GAA 2072/4885FAAH 73/4885CTSB 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.